BiomX

PHGE

Market cap $4.09M

BiomX (PHGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Proceeds to Support the Company's Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives Proceeds to Support the Company's Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives

BiomX Inc. (NYSE: PHGE) on Tuesday announced that the U.S. Food and Drug Administration (FDA) is continuing its evaluation of the nebulizer device used for drug administration in the company's Phase 2b trial of BX004 in cystic fibrosis patients.

The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial

BiomX Inc. ( PHGE ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Marina Wolfson - CFO & Secretary Jonathan Solomon - CEO & Director Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd.

Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success

BiomX believes that it has fully addressed the FDA's queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications on the nebulizer has also been addressed

U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification regarding the BX004 drug candidate

BiomX Inc. (NYSE:PHGE ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Jonathan Eitan Solomon - CEO & Director Marina Wolfson - CFO & Secretary Conference Call Participants I-Eh Jen - Laidlaw & Company (UK) Ltd., Research Division Joseph Pantginis - H.C.

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study